

117
Translation

ATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 2611WO0P	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/JP00/03558	International filing date (day/month/year) 01 June 2000 (01.06.00)	Priority date (day/month/year) 03 June 1999 (03.06.99)
International Patent Classification (IPC) or national classification and IPC G01N 33/50, 33/15, A61K 45/00, A61P 37/04, 37/06, 20/00, C12N 15/12, C12Q 1/02		
Applicant TAKEDA CHEMICAL INDUSTRIES, LTD.		

<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of <u>3</u> sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of _____ sheets.</p>
<p>3. This report contains indications relating to the following items:</p> <p>I <input checked="" type="checkbox"/> Basis of the report</p> <p>II <input type="checkbox"/> Priority</p> <p>III <input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</p> <p>IV <input type="checkbox"/> Lack of unity of invention</p> <p>V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</p> <p>VI <input type="checkbox"/> Certain documents cited</p> <p>VII <input type="checkbox"/> Certain defects in the international application</p> <p>VIII <input type="checkbox"/> Certain observations on the international application</p>

Date of submission of the demand 03 August 2000 (03.08.00)	Date of completion of this report 21 June 2001 (21.06.2001)
Name and mailing address of the IPEA/JP	Authorized officer
Facsimile No.	Telephone No.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/JP00/03558

I. Basis of the report

1. With regard to the elements of the international application:*

- ☒ the international application as originally filed
- ☐ the description:
pages _____, as originally filed
pages _____, filed with the demand
pages _____, filed with the letter of _____
- ☐ the claims:
pages _____, as originally filed
pages _____, as amended (together with any statement under Article 19
pages _____, filed with the demand
pages _____, filed with the letter of _____
- ☐ the drawings:
pages _____, as originally filed
pages _____, filed with the demand
pages _____, filed with the letter of _____
- ☐ the sequence listing part of the description:
pages _____, as originally filed
pages _____, filed with the demand
pages _____, filed with the letter of _____

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language _____ which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. ☐ The amendments have resulted in the cancellation of:

- ☐ the description, pages _____
- ☐ the claims, Nos. _____
- ☐ the drawings, sheets/fig _____

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rule 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims	1-16	YES
	Claims		NO
Inventive step (IS)	Claims	1-16	YES
	Claims		NO
Industrial applicability (IA)	Claims	1-16	YES
	Claims		NO

2. Citations and explanations

Document 1: Kathryn T. Hall et al., "Human CD100: a novel leukocyte semaphorin that promotes B-cell aggregation and differentiation", Proc. Natl. Acad. Sci. USA, Vol.93, pp. 11780-11785 (1996)

Document 2: William H. Robinson et al., "Extensive polymorphism in the extra cellular domain of the mouse B cell differentiation antigen Lyb-2 CD72", The Journal of Immunology, Vol. 149, pp. 880 to 886

Concerning Claims 1 to 16

Document 1 discloses CD100 and its salt and Document 2 discloses CD72 and its salt. However, neither document discloses a screening method using the same.

発信人 日本国特許庁（国際調査機関）

出願人代理人

高橋 秀一

殿

あて名

〒532-0024

大阪府大阪市淀川区十三本町2-17-85
武田薬品工業株式会社知的財産部

P C T

調査用写しの受理通知書

（法施行規則第39条）
〔PCT規則25.1〕



PCT/JP00/03558

SA202

発送日（日．月．年）

04.07.00

出願人又は代理人

の書類記号

2611WOOP

重 要 な 通 知

国際出願番号

PCT/JP00/03558

国際出願日（日．月．年）

01.06.00

優先日（日．月．年）

03.06.99

出願人（氏名又は名称）

武田薬品工業株式会社

1. 国際調査機関と受理官庁が同一の機関でない場合、

国際出願の調査用写しを国際調査機関が下記の日に受理したので通知する。

国際調査機関と受理官庁が同一の機関である場合、

国際出願の調査用写しを下記の日に受理したので通知する。

04 日 07 月 00 年（受理の日）

2. ☒ 調査用写しには、コンピューター読取りが可能な形式によるヌクレオチド又はアミノ酸の配列表が添付されている。

3. 国際調査報告の作成期間

国際調査報告の作成期間は、上記受理の日から3箇月の期間又は優先日から9箇月の期間のいずれか遅く満了する期間である。

4. この通知書の写しは、国際事務局及び上記1の第1文が適用される場合には受理官庁に送付した。

名称及びあて名

日本国特許庁（ISA/JP）

郵便番号 100-8915 TEL 03-3592-1308

日本国東京都千代田区霞が関三丁目4番3号

様式PCT/ISA/202（1998年7月）

権限のある職員

特 許 庁 長 官